Lantern Pharma Inc. (LTRN) Earnings Call Transcript & Summary

Good morning, and welcome to Lantern Pharma's 2021 Annual Meeting of Stockholders. My name is Panna Sharma, and I'm President and CEO of Lantern Pharma. I will be presiding at the meeting today. Thank you all for attending. Also in attendance at the meeting today are members of our Board of Directors; also Dean Katsoupas and Michele Epstein of EisnerAmper, our public accounting firm and auditor. David Margrave, CFO and Secretary of Lantern Pharma, will also be acting as the secretary and inspector of elections for this meeting. Now let me give you an outline of the plan for this meeting. As described in the notice and proxy statement that has been distributed and also available in the tab, you are entitled to participate and vote at this meeting if you are a stockholder as of the close of business on March 26, 2021, that is the record date for this meeting; or if you hold a legal proxy for the meeting provided by your bank, broker or nominee. If you have a voting control number issued through Broadridge and wish to vote during this meeting, you may do so by clicking the Voting button on the lower right-hand portion of your screen. If you hold your common shares in your record name, the control number will be on your proxy card. If you hold your shares in street name, the control number should have been provided to you by your bank, broker or nominee. You may also ask questions during the meeting if you registered with your voting control number. [Operator Instructions] A digital copy of the notice and proxy statement is also available for your review. You may access that document by clicking on the Materials tab in the lower right-hand portion of your screen and then selecting the proxy statement document. An agenda that outlines the order of business for the meeting can also be found by clicking on the Materials tab in the lower right-hand portion of your screen. On today's agenda, there are 2 items. Item 1, we are voting to elect 6 directors to serve as members the Board of Directors for the company. They are Donald Jeff Keyser; Vijay Chandru; Leslie Kreis, Jr.; Franklyn Prendergast; David S. Silberstein; and myself, Panna Sharma. Item 2, we are voting to ratify the selection of EisnerAmper LLP as Lantern's independent registered public accounting firm for the current year. EisnerAmper was approved by the Board's Audit Committee, which is made up entirely of directors who are independent under NASDAQ listing rules. In attendance today are Dean Katsoupas and Michele Epstein of EisnerAmper LLP. They will be available to answer any questions during the last part of the meeting. David Margrave, our CFO and Secretary of Lantern Pharma, will act as secretary of this meeting, record the minutes and see that they have attached all the necessary documents and exhibits. Mr. Margrave will also act as the inspector of election of today's meeting. Mr. Margrave has taken the necessary oath and has advised that we have a quorum present. So this is an official meeting, and we can proceed with our business. During the meeting, we will address the matters described on the meeting agenda, and the meeting shall be conducted in accordance with the rules of conduct. The rules of conduct can be accessed by clicking on the Materials tab in the lower right-hand portion of your screen. Voting will be completed and an announcement will be made regarding the preliminary results, and then the formal meeting will be adjourned. Questions should be restricted to the procedures for the meeting and the proposals under consideration. Thank you for your understanding of that. If you're eligible to vote and have not submitted your ballot or proxy or if you want to change your vote, please cast your digital vote via the Voting button on the lower right-hand portion of your screen. Ballots will be tallied after we have voted on all matters on the agenda. Upon receipt of the ballots, the polls will officially be closed, and then the digital votes cast today will be counted in a final tally, along with the proxies that we've already previously received. We will announce the preliminary results of the voting at the end of the meeting. The polls are now open for the 2 items of business as of 11:05 a.m. Eastern daylight time. The first item of formal business is the election of the 6 directors to serve as members of the Board of Directors of Lantern Pharma until the next Annual Meeting of Stockholders and until their successors are duly elected and qualified. The second item of formal business is to ratify or reject the Audit Committee's selection of EisnerAmper LLP as the company's independent registered public accounting firm for the current fiscal year ending December 31, 2021. Are there any questions on these proposals? Okay. The floor is now open for discussion concerning the proposals. If you registered with your voting control number and wish to submit a question, please refer to the Q&A button located in the lower right-hand portion of your screen. We will respond to as many questions as practical. Okay. Voting is by proxy and digital ballot. Each share of common stock is entitled to 1 vote. Let me remind you that if you already have sent in your signed proxy, there's no need for you to cast a ballot now unless you wish to change the vote that you put on the proxy. The individuals named in the proxy or any of them will vote your shares as indicated on the proxy that you already have mailed or delivered to us. As a reminder, if you are voting today, please make sure you have your voting control number issued by Broadridge and click the Voting button on the lower right-hand portion of your screen. We'll now provide some additional time for the submission of voting. [Voting]

Thank you. There being no further business to come before the meeting, I declare the polls are now closed for all items of business as of 11:08 Eastern daylight time. No additional ballots, proxies or votes and no changes or revocations will be accepted. The proxies and digital ballots will now be tabulated by the inspector of the election. At this time, we'll be happy to take any stockholder questions. Does anyone have a question? Okay. Based upon preliminary information provided by the inspector of election, David Margrave, I can report that each of the nominees for the Board of Directors, namely Donald Jeff Keyser; Vijay Chandru; Leslie Kreis; Franklyn Prendergast; and David S. Silberstein; along with myself, Panna Sharma, have been duly elected to hold office until the next Annual Meeting of Stockholders and until their successors are duly elected and qualified. The proposal to ratify the selection of EisnerAmper LLP as the independent registered public accounting firm of Lantern Pharma for the current year has received a majority of the votes cast and therefore, is adopted. The final results of voting, including any ballots and proxies recorded during this meeting, will be set forth in the report of the inspector of election and will be included in the minutes of the meeting. The final results will also be reported in a Form 8-K to be filed with the SEC within 4 business days following this meeting. Before adjourning, I would like to thank each stockholder who sent in a proxy for this meeting, and I especially would like to thank you for those that are here in attendance today. The meeting is now adjourned.